Sjögren's disease & overlap diseases
Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sjögren's disease patients
Authors' conclusion
Abatacept has limited effects on salivary gland histology in SjD patients after 24 weeks of treatment.
Study context
- Population
- Sjögren's disease (SjD) patients from the Dutch ASAP-II and ASAP-III trials and the international abatacept trial (IM101,603) with a labial or parotid salivary gland biopsy at baseline and after 24 weekslabial 13, parotid 28
- Participants
- 41 patients
- Comparison
- Abatacept vs placebo for 24 weeks: salivary gland histopathology
- Abataceptn = 25
- Placebon = 16reference
- Primary endpoint
- SjD-related histopathological features of salivary gland biopsies before and after treatment
- Follow-up
- 24 weeks
Methodological detailssalivary gland biopsies at baseline and after 24 weeks, labial (n=13) or parotid (n=28) biopsies
- Salivary gland biopsies at baseline and after 24 weeks
- Labial (n=13) or parotid (n=28) biopsies
Primary result
As reported in the abstract
- Parotid glands: number of IgA plasma cells increased in the abatacept group after 24 weeks
- p=0.049
- Parotid glands: CD20+ B-cells/mm² increased vs baseline in the placebo group
- p=0.021
Further findings
Baseline histopathology as predictor of response to abatacept (CRESS or ClinESSDAI responders vs non-responders)
- No evident differences in baseline histopathological parameters between responders and non-responders
Original publication
Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sjögren's disease patients. Clin Exp Rheumatol. Published 18 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →